United States Biotechnology & Medical Research

Yarrow Bioscience, Inc. (YARW)

Track

Track

The most recent insider trading activity occurred on January 15, 2025, when Patrick G. Lepore executed a purchase of 15,000 shares. This transaction represents the latest in a series of acquisitions by the same individual, reflecting a consistent pattern of accumulation over several years.
Ticker: YARW Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Yarrow Bioscience, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Purchase
Price
309.19
Quantity 89,105 +25.0%
Value US$4,145,169
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Purchase
Price
213.32
Quantity 4,302 +1.6%
Value US$3,166,110
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Purchase
Price
128.20
Quantity 48,356 -26.9%
Value US$894,845
Harsch Mutya Chief Legal Officer and GC Officer
Transaction date
Purchase
Price
2.50
Quantity 10,000 +78.6%
Value US$25,000
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Planned purchase
Price
1.02
Quantity 12,500 +25.0%
Value US$12,699
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.23
Quantity 338,897 -5.9%
Value US$755,740
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Purchase
Price
7.41
Quantity 12,500 +100.0%
Value US$92,562
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
2.37
Quantity 4,219,409 +18.4%
Value US$9,999,999
2.5
LEPORE PATRICK G Non-Executive Director
Transaction date
Planned purchase
Price
1.71
Quantity 50,000 +inf%
Value US$85,425
3.2
Domzalski David President and CEO Executive Director
Transaction date
Purchase
Price
1.38
Quantity 75,000 +6.0%
Value US$103,568
3.7
Saik Andrew Chief Financial Officer Officer
Transaction date
Purchase
Price
1.46
Quantity 40,000 +13.3%
Value US$58,480
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
1.85
Quantity 2,702,702 +13.4%
Value US$4,999,999
Presidio Partners 2007 GP, L.P.
Transaction date
Sale
Price
7.65
Quantity 12,500 -20.4%
Value US$95,625
Presidio Partners 2007 GP, L.P.
Transaction date
Sale
Price
7.65
Quantity 487,500 -20.4%
Value US$3,729,375
Remeditex Ventures LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 100,000 +6.7%
Value US$1,700,000
Cha Albert Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 35,686 +inf%
Value US$606,662
Cha Albert Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 258,432 +inf%
Value US$4,393,344
Vivo Capital VIII, LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 35,686 +inf%
Value US$606,662
Vivo Capital VIII, LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 258,432 +inf%
Value US$4,393,344
venBio Global Strategic Fund II L.P. Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 265,000 +inf%
Value US$4,505,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-16 2025-01-15 B Purchase
2.5
LEPORE PATRICK G
Non-Executive Director
89,105 +25.0%
309.19
US$4,145,169 		89,105 +25.0% 309.19 US$4,145,169
2023-11-17 2023-11-15 B Purchase
2.5
LEPORE PATRICK G
Non-Executive Director
4,302 +1.6%
213.32
US$3,166,110 		4,302 +1.6% 213.32 US$3,166,110
2023-03-22 2023-03-20 B Purchase
2.5
LEPORE PATRICK G
Non-Executive Director
48,356 -26.9%
128.20
US$894,845 		48,356 -26.9% 128.20 US$894,845
2023-03-22 2023-03-20 B Purchase
Harsch Mutya

Chief Legal Officer and GC

Officer
10,000 +78.6%
2.50
US$25,000 		10,000 +78.6% 2.50 US$25,000
2021-12-02 2021-11-30 PP Planned purchase
2.5
LEPORE PATRICK G
Non-Executive Director
12,500 +25.0%
1.02
US$12,699 		12,500 +25.0% 1.02 US$12,699
2021-08-16 2021-08-12 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
338,897 -5.9%
2.23
US$755,740 		338,897 -5.9% 2.23 US$755,740
2021-03-16 2021-03-15 B Purchase
2.5
LEPORE PATRICK G
Non-Executive Director
12,500 +100.0%
7.41
US$92,562 		12,500 +100.0% 7.41 US$92,562
2021-02-01 2021-01-28 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
4,219,409 +18.4%
2.37
US$9,999,999 		4,219,409 +18.4% 2.37 US$9,999,999
2020-12-07 2020-12-03 PP Planned purchase
2.5
LEPORE PATRICK G
Non-Executive Director
50,000 +inf%
1.71
US$85,425 		50,000 +inf% 1.71 US$85,425
2020-09-08 2020-09-08 B Purchase
3.2
Domzalski David

President and CEO

Executive Director
75,000 +6.0%
1.38
US$103,568 		75,000 +6.0% 1.38 US$103,568
2020-09-08 2020-09-08 B Purchase
3.7
Saik Andrew

Chief Financial Officer

Officer
40,000 +13.3%
1.46
US$58,480 		40,000 +13.3% 1.46 US$58,480
2020-06-11 2020-06-09 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
2,702,702 +13.4%
1.85
US$4,999,999 		2,702,702 +13.4% 1.85 US$4,999,999
2018-07-26 2018-07-24 S Sale Presidio Partners 2007 GP, L.P.
12,500 -20.4%
7.65
US$95,625 		12,500 -20.4% 7.65 US$95,625
2018-07-26 2018-07-24 S Sale Presidio Partners 2007 GP, L.P.
487,500 -20.4%
7.65
US$3,729,375 		487,500 -20.4% 7.65 US$3,729,375
2018-01-29 2018-01-25 B Purchase Remeditex Ventures LLC Large shareholder
100,000 +6.7%
17.00
US$1,700,000 		100,000 +6.7% 17.00 US$1,700,000
2018-01-29 2018-01-25 B Purchase Cha Albert Non-Executive Director
35,686 +inf%
17.00
US$606,662 		35,686 +inf% 17.00 US$606,662
2018-01-29 2018-01-25 B Purchase Cha Albert Non-Executive Director
258,432 +inf%
17.00
US$4,393,344 		258,432 +inf% 17.00 US$4,393,344
2018-01-29 2018-01-25 B Purchase Vivo Capital VIII, LLC Large shareholder
35,686 +inf%
17.00
US$606,662 		35,686 +inf% 17.00 US$606,662
2018-01-29 2018-01-25 B Purchase Vivo Capital VIII, LLC Large shareholder
258,432 +inf%
17.00
US$4,393,344 		258,432 +inf% 17.00 US$4,393,344
2018-01-29 2018-01-25 B Purchase venBio Global Strategic Fund II L.P. Large shareholder
265,000 +inf%
17.00
US$4,505,000 		265,000 +inf% 17.00 US$4,505,000
Explore more

More insider trading research around Yarrow Bioscience, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America